Faricimab
Faricimab (INN[1]) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema.
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized |
Target | VEGF-A, angiopoietin 2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
KEGG |
This drug is being developed by Hoffmann-La Roche. As of 2018, faricimab is undergoing Phase III trials.
References
- World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.